You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)發布澤布替尼及替雷利珠單抗之最新數據
阿思達克 06-16 08:18
百濟神州(06160.HK)公布,於今年6月12日在第25屆歐洲血液學協會(EHA)線上年會上公佈BTK抑製劑百悅澤(澤布替尼)用於治療復發/難治性(R/R)邊緣區淋巴瘤(MZL)和其他B細胞惡性腫瘤以及抗PD-1抗體百澤安(替雷利珠單抗)用於治療R/R NK/T細胞淋巴瘤的數據。

澤布替尼在包括R/R MZL在內的多項適應症中展示了令人欣慰的有效性和安全性;一項用於治療R/R MZL患者的潛在註冊性2期臨床試驗目前已完成患者入組。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account